Per-domain healthcare-framework revenue is set out on the Regulatory page — each domain has its own market sizing with a Jersey-specific direct-revenue and multiplier estimate. This page aggregates those, adds the adjacent-industry multipliers that follow a well-regulated jurisdiction (hospitality, professional services, financial services, real estate, aviation, digital infrastructure, education, ancillary regulated industries), sets the total against Jersey's current £5.5B GVA, and covers a specific opportunity that emerged from a Jacob Schofield conversation: Jersey's existing funds services industry as the natural home for medical-IP-holding vehicles.
At the high end of the ranges below, the framework at maturity could contribute around three-quarters of the share of Jersey GVA that financial services built over five decades — with the additional characteristic that the finance industry itself benefits from the buildup rather than being displaced by it.
Aggregated across the seven regulatory domains.
Each row combines direct healthcare-framework revenue with the adjacent-industry multiplier that follows from it. All ranges are annual, at framework maturity (~Y7-Y10). Sources for each figure are cited in the individual domain sections on the Regulatory page.
| Domain | Direct revenue | Multiplier | Total contribution |
|---|---|---|---|
| 1 · Reproductive medicine | £85-225M | £35-90M | £120-315M |
| 2 · Psychedelic therapeutics | £30-110M | £10-35M | £40-145M |
| 3 · Cannabis therapeutics | £40-170M | £15-70M | £55-240M |
| 4 · Advanced therapeutics + longevity | £50-255M | £20-100M | £70-355M |
| 5 · Clinical trial pathways | £10-40M | £5-15M | £15-55M |
| 6 · Advanced diagnostics | £85-340M | £35-135M | £120-475M |
| 7 · Aesthetic medicine | £20-85M | £10-35M | £30-120M |
| Aggregate — seven domains | £320M-£1.2B | £130M-£480M | £450M-£1.7B |
Against Jersey's current economic base.
Jersey's total Gross Value Added in 2023 was approximately £5.5 billion (Government of Jersey Statistics Unit, 2024). Financial services contributed roughly £2.3 billion of that — around 40% of the island economy — the result of five decades of framework buildup starting in the 1960s. The mature health-innovation framework, at the mid-to-high end of the ranges above, would contribute £1.0-1.7 billion in direct plus multiplier value: roughly 18-31% of current Jersey GVA. Even the conservative low end (£450M/year) would be roughly 8% of current GVA — a significant new sector in its own right.
The full ramp-up curve is unlikely to match finance's five-decade timeline, because much of the framework and its multipliers can be operational within 5-10 years of legislative passage rather than requiring a slower international-reputation buildup. But an early growth ceiling is set by the physical constraints of the island — how many clinicians can be recruited and retained, how much clinical property can be built, how much medical tourism the island's accommodation and transport infrastructure can absorb — and by the pace of framework refinement itself.
Realistic buildup curve.
Directly-attributable annual revenue from patients using the framework, aggregated across all seven domains, at three realistic horizons.
What sits behind the framework.
A well-regulated health-innovation jurisdiction attracts a stack of supporting industries — the same phenomenon Jersey has seen in finance, where the core financial-services activity draws in legal, accountancy, corporate services, real estate, and hospitality behind it. For health innovation, the multiplier map looks like this:
Hospitality
Patient stays, families, accompanying persons. Higher-value, longer-duration than leisure. Programme + trial patients typically 7-30 days on-island.
Est. £40-145M/year at maturityProfessional services (legal + accounting)
Regulatory work, hosting agreements, IP structuring, corporate structures for biotech partners, cross-border employment.
Est. £15-60M/year at maturityFinancial services (base)
Biotech investment vehicles, clinical-trial funding structures, patient-financing products, private-office structures for wealthy medical-tourism patients.
Est. £25-95M/year at maturityReal estate + construction
Clinical property, researcher and staff housing, patient accommodation beyond hotels, medical office fit-out, research-facility development.
Est. £20-70M/year at maturityAviation + logistics
Private-jet handling, air-link investment, biological-sample logistics, controlled-drug movement, medical-device customs handling.
Est. £5-30M/year at maturityDigital + health-data infrastructure
GDPR-compliant clinical data hosting, telemedicine infrastructure, outcome-registry technology, cyber-security services for clinical data.
Est. £10-40M/year at maturityEducation + talent
Clinical training programmes, potential medical-school partnerships, technical training, translational-research talent development.
Est. £5-20M/year at maturityAncillary regulated industries
Medical-device certification bodies, accreditation services, GxP consultancy, health-economics research, clinical-outcome research contracting.
Est. £10-20M/year at maturityMedical IP structuring via Jersey funds services.
Beyond the general "financial services" multiplier line above, there is a specific opportunity that emerges when a health-innovation jurisdiction sits inside a mature funds-services economy: Jersey becomes the natural domicile for medical-IP-holding vehicles.
Medical IP has become a distinct asset class over the last decade — patents, licensing rights, royalty streams from approved therapeutics, orphan-drug rights, biotech IP monetisation. Companies like Royalty Pharma (Nasdaq-listed) operate this at multi-billion-dollar scale. The asset class is growing quickly as biotech valuations shift from equity-based to IP-based structures, and as pharmaceutical companies increasingly separate IP ownership from clinical operations.
Jersey has one of the world's most sophisticated funds-services industries — approximately £500 billion in assets under administration across private equity, venture capital, family-office, and specialty fund vehicles. That infrastructure is well-suited to host medical-IP holding vehicles: sophisticated trust and corporate structures, mature fund administration, tax neutrality, and strong regulatory reputation via the JFSC.
The synergy is direct. Patients coming to Jersey for the regulatory framework generate outcome data. Outcome data supports biotech partnerships. Biotech partnerships generate IP. That IP could be structured through Jersey funds services and held on Jersey balance sheets — a full-stack economic capture rather than sending the highest-value part of the chain offshore. The framework attracts the clinical work; the funds industry monetises the IP that clinical work produces; both benefit.
An early move: Plenty Biologics
Jacob Schofield has founded Plenty Biologics, an early Jersey entrepreneurial move into medical-IP structuring — building Jersey-domiciled vehicles specifically for medical-IP management and monetisation. It is one of the first practical examples of the "finance-industry-benefits-directly" thesis: not an aspirational future but a company being built now, on the specific premise that Jersey funds services are the right home for a growing global medical-IP market.
The framework opportunity for Jersey is to make this thesis structural rather than incidental: authorised Jersey-domiciled vehicle structures specifically designed for medical-IP management, a formal JFSC posture that treats medical-IP structuring as a strategic sub-sector alongside existing fund-services specialisms, and coordination with the health-innovation regulatory framework so that clinical work and IP monetisation reinforce each other.
Reference: plentybiologics.com
Direct healthcare-framework revenue across seven domains plus multiplier industries, before the medical-IP structuring upside sketched above. Set against Jersey's current total GVA of ~£5.5B (Government of Jersey Statistics Unit, 2023), the mature framework represents roughly 8-31% of the current island economy. At the high end that is around three-quarters the scale of today’s finance industry, built over a much shorter period; even the low end is a significant new sector.
What the ranges assume.
The ranges above are illustrative not definitive. They assume: (a) the framework legislation passes broadly as sketched in the political case; (b) at least one flagship biotech partner engages in the first framework-mature years; (c) international medical-tourism patient flows respond to the regulatory offer as they historically have for Switzerland (finance, private medicine) and Singapore (medical tourism); (d) Jersey does not attempt to compete on price against lower-cost jurisdictions — the offer is quality, not cost.
Downside scenario. Framework passes but international demand disappoints and only Jersey residents plus a small UK inflow use the services. Still produces £40-120M/year at maturity, primarily via diagnostics, clinical trials and licensed metabolic medicine for Jersey residents and UK patients within easy travel distance. Not transformational but net-positive.
Upside scenario. Jersey becomes the recognised international standard for early-phase clinical trials and for research into polygenic embryo screening and longevity therapeutics, with successful trials allowing some of that research to become approved treatment. Jersey funds services capture meaningful medical-IP structuring flows. Could reach £2.5-3B/year total contribution by the late 2030s.
What moves the outcome. The framework detail (how well-scaffolded the regulatory design is), the regulator resourcing (JFSC + JCC + a new Health Innovation Framework Office funded to the pace of the opportunity), whether the physical infrastructure emerges alongside the legal framework (research facilities, clinical property, expanded accommodation), and whether the funds industry treats medical-IP structuring as a strategic sub-sector rather than incidental work.
The competitive window.
Every one of the seven domains covered on the Regulatory page has a global regulatory window that is open now and will not stay open for a decade. The FDA's 2024 rejection of MDMA-assisted therapy has left room for a jurisdiction that can build the evidence properly; the EU is beginning to consider its position on advanced therapeutics. First-mover status matters — the jurisdiction that publishes the first serious, considered framework for n=1 trial pathways, or the first rigorous research programme for polygenic embryo screening, becomes the international reference. Small, well-governed jurisdictions have won this position historically: Delaware in corporate law, Switzerland in finance, Singapore in trade dispute resolution. Health innovation is the next domain where this pattern is available, and Jersey is unusually well positioned to take it — provided the framework is built with the same seriousness the island brought to its finance industry, and the finance industry is engaged as a beneficiary of the buildup rather than a bystander to it.